{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Zepbound",
    "query": {
      "intervention": "Zepbound"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 27,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Zepbound&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-02T09:23:54.134Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07220473",
      "title": "Tirzepatide to Slow Biological Aging",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Aging",
        "LONGEVITY 1"
      ],
      "interventions": [
        {
          "name": "Zepbound",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Medical Branch, Galveston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "55 Years to 70 Years"
      },
      "enrollment_count": 90,
      "start_date": "2026-02-27",
      "completion_date": "2028-01",
      "has_results": false,
      "last_update_posted_date": "2026-03-24",
      "last_synced_at": "2026-09-02T09:23:54.134Z",
      "location_count": 1,
      "location_summary": "Galveston, Texas",
      "locations": [
        {
          "city": "Galveston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07220473"
    },
    {
      "nct_id": "NCT07640139",
      "title": "Estimating the Impact of Obesity Medications on Clinical and Economic Outcomes",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Incretin-based therapies (GLP-1 and GLP-1/GIP)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Indiana University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 125000,
      "start_date": "2026-01-01",
      "completion_date": "2029-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-10",
      "last_synced_at": "2026-09-02T09:23:54.134Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07640139"
    },
    {
      "nct_id": "NCT06584916",
      "title": "A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Obesity",
        "Overweight"
      ],
      "interventions": [
        {
          "name": "Orforglipron",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 376,
      "start_date": "2024-09-13",
      "completion_date": "2025-11-21",
      "has_results": false,
      "last_update_posted_date": "2026-06-04",
      "last_synced_at": "2026-09-02T09:23:54.134Z",
      "location_count": 27,
      "location_summary": "Birmingham, Alabama • Pelham, Alabama • Santa Ana, California + 21 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Pelham",
          "state": "Alabama"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        },
        {
          "city": "Spring Valley",
          "state": "California"
        },
        {
          "city": "Tustin",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06584916"
    },
    {
      "nct_id": "NCT07702461",
      "title": "Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Obesity & Overweight",
        "Diabetes (DM)"
      ],
      "interventions": [
        {
          "name": "Glucagon-Like Peptide-1 Agonist (GLP-1)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ohio State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 300,
      "start_date": "2026-06-12",
      "completion_date": "2027-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-24",
      "last_synced_at": "2026-09-02T09:23:54.134Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07702461"
    },
    {
      "nct_id": "NCT06745128",
      "title": "Tirzepatide for Obesity and Meth Use Disorder",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Obesity",
        "Methamphetamine Use Disorder"
      ],
      "interventions": [
        {
          "name": "Tirzepatide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 45,
      "start_date": "2025-02-03",
      "completion_date": "2026-03-31",
      "has_results": false,
      "last_update_posted_date": "2025-06-12",
      "last_synced_at": "2026-09-02T09:23:54.134Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06745128"
    },
    {
      "nct_id": "NCT07554638",
      "title": "Incretin Therapies in Obesity-related HFpEF",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Heart Failure, Diastolic",
        "Heart Failure With Preserved Ejection Fraction",
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Tirzepatide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2026-08-07",
      "completion_date": "2030-04",
      "has_results": false,
      "last_update_posted_date": "2026-08-24",
      "last_synced_at": "2026-09-02T09:23:54.134Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07554638"
    },
    {
      "nct_id": "NCT06374875",
      "title": "Fibrosis Lessens After Metabolic Surgery",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)",
        "Non-Alcoholic Fatty Liver Disease",
        "Metabolic Dysfunction-Associated Steatohepatitis (MASH)",
        "Liver Fibrosis",
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Metabolic surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "Incretin-Based Therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "The Cleveland Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 120,
      "start_date": "2024-07-11",
      "completion_date": "2029-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-31",
      "last_synced_at": "2026-09-02T09:23:54.134Z",
      "location_count": 4,
      "location_summary": "Phoenix, Arizona • Indianapolis, Indiana • Rochester, Minnesota + 1 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06374875"
    },
    {
      "nct_id": "NCT06803888",
      "title": "Bariatric Surgery vs. Semaglutide vs. Tirzepatide",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Obesity and Obesity-related Medical Conditions"
      ],
      "interventions": [
        {
          "name": "Bariatric Surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "Semaglutide",
          "type": "DRUG"
        },
        {
          "name": "Tirzepatide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Ali Aminian",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 125,
      "start_date": "2025-01-29",
      "completion_date": "2027-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-18",
      "last_synced_at": "2026-09-02T09:23:54.134Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06803888"
    },
    {
      "nct_id": "NCT07734870",
      "title": "Tirzepatide for Treatment of CCCA",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Central Centrifugal Cicatricial Alopecia (CCCA)"
      ],
      "interventions": [
        {
          "name": "Tirzepatide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 20,
      "start_date": "2026-09-15",
      "completion_date": "2028-05-25",
      "has_results": false,
      "last_update_posted_date": "2026-08-12",
      "last_synced_at": "2026-09-02T09:23:54.134Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Columbia, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Columbia",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07734870"
    },
    {
      "nct_id": "NCT06732245",
      "title": "Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Obesity and Overweight"
      ],
      "interventions": [
        {
          "name": "NA-931",
          "type": "DRUG"
        },
        {
          "name": "Tirzepatide",
          "type": "DRUG"
        },
        {
          "name": "NA-931 150 mg + no Tirzepatide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biomed Industries, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "19 Years to 80 Years"
      },
      "enrollment_count": 224,
      "start_date": "2026-08-15",
      "completion_date": "2027-12-15",
      "has_results": false,
      "last_update_posted_date": "2026-03-27",
      "last_synced_at": "2026-09-02T09:23:54.134Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • San Diego, California • San Francisco, California + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06732245"
    }
  ]
}